PL3694505T3 - Związek i kompozycja do stosowania w leczeniu profilaktycznym i/lub terapeutycznym chorób ośrodkowego układu nerwowego charakteryzujących się spadkiem plastyczności neuronalnej, w szczególności charakteryzujących się spadkiem plastyczności synaptycznej - Google Patents

Związek i kompozycja do stosowania w leczeniu profilaktycznym i/lub terapeutycznym chorób ośrodkowego układu nerwowego charakteryzujących się spadkiem plastyczności neuronalnej, w szczególności charakteryzujących się spadkiem plastyczności synaptycznej

Info

Publication number
PL3694505T3
PL3694505T3 PL18773776.2T PL18773776T PL3694505T3 PL 3694505 T3 PL3694505 T3 PL 3694505T3 PL 18773776 T PL18773776 T PL 18773776T PL 3694505 T3 PL3694505 T3 PL 3694505T3
Authority
PL
Poland
Prior art keywords
decline
plasticity
preventive
diseases
compound
Prior art date
Application number
PL18773776.2T
Other languages
English (en)
Inventor
Philippe DANHIER
Pascale AZZAM
Original Assignee
Synapharm Industrial Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synapharm Industrial Synthesis filed Critical Synapharm Industrial Synthesis
Publication of PL3694505T3 publication Critical patent/PL3694505T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL18773776.2T 2017-10-13 2018-09-26 Związek i kompozycja do stosowania w leczeniu profilaktycznym i/lub terapeutycznym chorób ośrodkowego układu nerwowego charakteryzujących się spadkiem plastyczności neuronalnej, w szczególności charakteryzujących się spadkiem plastyczności synaptycznej PL3694505T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2017/5731A BE1025644B1 (fr) 2017-10-13 2017-10-13 Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale
PCT/EP2018/076133 WO2019072568A1 (fr) 2017-10-13 2018-09-26 Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique

Publications (1)

Publication Number Publication Date
PL3694505T3 true PL3694505T3 (pl) 2024-04-02

Family

ID=60164541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18773776.2T PL3694505T3 (pl) 2017-10-13 2018-09-26 Związek i kompozycja do stosowania w leczeniu profilaktycznym i/lub terapeutycznym chorób ośrodkowego układu nerwowego charakteryzujących się spadkiem plastyczności neuronalnej, w szczególności charakteryzujących się spadkiem plastyczności synaptycznej

Country Status (14)

Country Link
US (2) US20200237812A1 (pl)
EP (1) EP3694505B1 (pl)
CN (1) CN111315373A (pl)
BE (1) BE1025644B1 (pl)
BR (1) BR112020007341A2 (pl)
CA (1) CA3079410A1 (pl)
DK (1) DK3694505T3 (pl)
ES (1) ES2965493T3 (pl)
FI (1) FI3694505T3 (pl)
MX (1) MX2020003844A (pl)
PL (1) PL3694505T3 (pl)
PT (1) PT3694505T (pl)
SI (1) SI3694505T1 (pl)
WO (1) WO2019072568A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383520B2 (en) 2019-05-16 2025-08-12 Synapharm Industrial Synthesis Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384751A1 (fr) * 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
IT1237435B (it) 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
FR2704391B1 (fr) * 1993-04-27 1995-06-02 Boiron Complément nutritionnel absorbable pour faciliter l'adaptation au stress quodidien.
US7148192B2 (en) * 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
AU2007212683A1 (en) 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
US8889194B2 (en) * 2006-06-21 2014-11-18 Harlan Clayton Bieley Smoking cessation with body weight maintenance and nutritional supplement
US20080249178A1 (en) * 2007-03-22 2008-10-09 Guosong Liu Magnesium compositions and uses thereof for increasing lifespan
MY174384A (en) * 2007-03-22 2020-04-15 Neurocentria Inc Magnesium compositions and uses thereof
US20110072525A1 (en) * 2009-09-22 2011-03-24 Effat Emamian Compositions and methods for the treatment of psychiatric and neurological disorders
FI129157B (en) * 2012-05-28 2021-08-13 Biohit Oyj Composition for use in reducing the incidence of or preventing severe headaches
AU2014235034A1 (en) * 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements
EP3160459A1 (en) * 2014-06-24 2017-05-03 Dedraf Holding B.V. New mineral composition

Also Published As

Publication number Publication date
FI3694505T3 (fi) 2023-12-20
BE1025644A1 (fr) 2019-05-10
PT3694505T (pt) 2023-12-05
CN111315373A (zh) 2020-06-19
BR112020007341A2 (pt) 2020-10-06
US20200237812A1 (en) 2020-07-30
MX2020003844A (es) 2020-11-06
EP3694505A1 (fr) 2020-08-19
EP3694505B1 (fr) 2023-10-04
BE1025644B1 (fr) 2019-05-15
CA3079410A1 (en) 2019-04-18
US20220008455A1 (en) 2022-01-13
ES2965493T3 (es) 2024-04-15
DK3694505T3 (da) 2024-01-02
SI3694505T1 (sl) 2024-02-29
WO2019072568A1 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
ZA201900519B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
PL3407889T3 (pl) Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
IL246579B (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson&#39;s disease
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2017006437A (es) Compuestos espiroisoquinolin-1,4&#39;-piperidinicos con actividad multimodal contra el dolor.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
IL277238A (en) Modified oligonucleotides for use in the treatment of tauopathy
EP3411399A4 (en) TECHNOLOGY FOR ANTIBODY-ACTIVE SYNERGISM FOR THE TREATMENT OF DISEASES
KR102316727B9 (ko) 아토피성 질환 예방 또는 치료용 약학적 조성물
GB2561747B (en) Composition for treating motor neuron diseases and use thereof
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PT3694505T (pt) Composto e composição para utilização no tratamento preventivo e/ou curativo de doenças do sistema nervoso central caracterizadas por um diminuição da elasticidade neuronal, caracterizado particularmente por uma diminuição da elasticidade sináptica
PH12018502568A1 (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
HK1248119A1 (zh) 有机氧化砷化合物和mtor抑制剂的药物组合
IL265976A (en) Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
PT3408373T (pt) Estirpe bacteriana como agente para evitar e/ou tratar distúrbios respiratórios
HK1242961A (en) Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
HK1242961A1 (en) Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
HK1244003A1 (en) Spiro-isoquinoline-1,4&#39;-piperidine compounds having multimodal activity against pain